Skip to content
Open access

Nano-RAPID: Integrated Diagnosis for Sarcoma Using a Nanopore Sequencer.

Sep 2026 · Genes, Chromosomes and Cancer · Vol 65 9, pp. e70174 · 0 citations · 25 references
Medicine

TL;DR

Nano-RAPID could be introduced in low-equipped hospitals to assist non-specialized pathologists diagnosing sarcoma and may be a promising adjunctive for sarcoma diagnosis, suggesting faster and cost-effective analyses.

Abstract

Pathological diagnosis of sarcoma is challenging. Although high-throughput sequencing and methylation array aid sarcoma diagnosis and are routine in high-income countries, access to these genetic/epigenetic analyses in many countries, including Japan, remains limited. Nanopore sequencing is an easy, fast, and cost-effective high-throughput sequencing alternative. Nanopore sequencers read long-read DNA to detect fusion DNA and 5-methyl-cytosine in single nucleotide resolution, enabling real-time basecalling for selective enrichment of regions of interest via "adaptive sampling." Nanopore sequencing of Raw DNA with Adaptive sampling for Prompt Integrated Diagnosis (Nano-RAPID) was developed to test its diagnostic utility. This study included 22 retrospective and nine prospective cases. DNA extracted from fresh/frozen tissue was sequenced for 46-98 h, followed by approximately 12 h of data analysis. Consequently, disease-specific/characteristic fusion genes were detected in 10 retrospective and six prospective cases. Disease-specific single nucleotide variants were detected in three cases, while disease-specific amplifications were detected in two retrospective cases. Monosomy, trisomy, and chromosomal instability were also detected. Methylation analyses accurately classified 15 retrospective and five prospective cases. Collectively, correct tumor types were identified using at least one modality in 19 retrospective and nine prospective cases. Halving the consumables and re-analyzing 24-h data yielded nearly equivalent results, suggesting faster and cost-effective analyses. In conclusion, Nano-RAPID may be a promising adjunctive for sarcoma diagnosis. Nano-RAPID could be introduced in low-equipped hospitals to assist non-specialized pathologists diagnosing sarcoma. Since this study remains exploratory, further studies with larger cohort should be needed.

Read PDF

Similar papers

Review Open access Sep 2026

The transformative impact of ultra-rapid nanopore sequencing in precision medicine

Nanopore sequencing has emerged as a transformative technology, offering unprecedented speed, ultra-long reads, and portability at a comparatively low cost. These attributes are fundamentally reshaping clinical diagnostics and personalized medicine. This review synthesizes the technological advancements driving nanopor...

S. Grasedieck, B. Keating, Stephen Yip et al. · 0 citations
Open access Aug 2026

101 Independent replication and validation of nanopore-based long read sequencing and methylome classification for rapid brain tumour diagnosis

Integrated histopathological-molecular analysis is essential to diagnose and guide precision therapies in brain tumours. Whilst standard of care (SoC) diagnostics takes weeks, long read sequencing (LRS) on Oxford Nanopore Technology (ONT) platform and bioinformatics research tools provide rapid diagnosis within h...

Vassili Crispi, L. Ames, J. Stockton et al. · 0 citations
Review Open access Sep 2026

Next-Generation Sequencing in Translational Sarcoma Research: Biological Insights and Emerging Directions

This review summarizes the main research applications of next-generation sequencing in sarcoma, with particular attention to mutation and variant discovery, fusion detection, biomarker development, assay validation, multi-omics integration, and the boundaries between exploratory research and clinical implementation.

A. de Vita, Sara Violani, G. Miserocchi et al. · 0 citations
Review Open access Sep 2026

CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer.

Although pre-analytical limitations remain to be fully characterized, integrating CRISPR into the diagnostic workflow may contribute to a rapid, cost-effective, and highly specific framework for the early detection of PDAC.

M. A. Rocco, Milda Kirvaitytė, Giulia Lencioni et al. · 0 citations
Open access Sep 2026

A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring

Background Circulating tumor DNA (ctDNA) analysis has revolutionized minimal residual disease (MRD) monitoring, but conventional tumor-informed amplicon-based sequencing (AMP) is limited by the narrow variant capacity and diversity. Hybrid capture-based sequencing (HYB) is more versatile and enables both tumor-informed...

T. Nguyen, Van-Anh Nguyen Hoang, C. Huynh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.